Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Gi Innovation Inc. manages a patent portfolio in the Biotechnology & Pharmaceuticals technology area with 3 pending office actions currently under review. The data shows that these matters are distributed across 3 distinct art units, which suggests that the pending applications cover a variety of technical subjects within the field. This distribution requires the applicant to address the specific standards and guidelines of 3 different administrative divisions.
The prosecution involves 3 distinct examiners, meaning that each pending matter is being evaluated by a different individual. STOICA, ELLY GERALD is the busiest examiner for this portfolio, currently handling 1 pending office action. Because no single examiner is responsible for more than 1 pending office action, the prosecution strategy must be tailored to the individual preferences and examination styles of 3 separate people.
The lack of overlap among the 3 distinct examiners and 3 distinct art units indicates a decentralized prosecution environment. Insights gained from one of the 3 pending office actions may not be applicable to the others. Practitioners should focus on the unique technical requirements of each art unit and the specific feedback from each examiner to move the portfolio forward effectively.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (33%) |
| Double-patenting + other | 2 (67%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| STOICA, ELLY GERALD | 1 | 66.9% | +22.5% |
| REGLAS, GEORGIANA C | 1 | 37.7% | +36.1% |
| D' AMBROSIO, THEA | 1 | 55.3% | +56.1% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18003123 | FUSION PROTEIN COMPRISING ANTI-LAG-3 ANTIBODY AND IL-2, AND USE THEREOF | D' AMBROSIO, THEA | 53d overdue |
| 18499840 | PHARMACEUTICAL COMPOSITION FOR CANCER TREATMENT COMPRISING FUSION PROTEIN INCLUDING IL-2 PROTEIN AND CD80 PROTEIN AND ANTICANCER DRUG | STOICA, ELLY GERALD | — |
| 18549558 | FORMULATION OF FUSION PROTEIN INCLUDING EXTRACELLULAR DOMAIN OF ALPHA SUBUNIT OF IGE FC RECEPTOR | REGLAS, GEORGIANA C | — |
| Art Unit | Apps |
|---|---|
| 1647 | 1 |
| 1651 | 1 |
| 1654 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18499840 | PHARMACEUTICAL COMPOSITION FOR CANCER TREATMENT COMPRISING FUSION PROTEIN INCLUDING IL-2 PROTEIN AND CD80 PROTEIN AND ANTICANCER DRUG | STOICA, ELLY GERALD | 1647 | §112DP | Non-Final OA | — | Pending | Nov 01, 2023 |
| 18549558 | FORMULATION OF FUSION PROTEIN INCLUDING EXTRACELLULAR DOMAIN OF ALPHA SUBUNIT OF IGE FC RECEPTOR | REGLAS, GEORGIANA C | 1651 | §103DP | Non-Final OA | — | Pending | Sep 07, 2023 |
| 18003123 | FUSION PROTEIN COMPRISING ANTI-LAG-3 ANTIBODY AND IL-2, AND USE THEREOF | D' AMBROSIO, THEA | 1654 | §103 | Final Rejection | 53d overdue | Pending | Dec 22, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial